Browse every story filed under this topic, curated from trusted publishers around the world.
With the recent launch of Novo Nordisk’s Wegovy pill opening the oral GLP-1 market for obesity, the company has now unveiled positive results that could tee up an expansion in semaglutide’s inaugural diabetes indication.
Read full story →You've seen all articles for #semaglutide.
Check back
soon
for new stories.